Heparin is an important anticoagulant drug, about one billion doses are produced annually. It is a polydisperse sulfated polysaccharide, and the inherent heterogeneity makes the analysis of heparin difficult. The global crisis resulting from adulterated heparin in 2008 has drawn renewed attention to the challenges that are associated with the quality control and characterization of this complex biological medicine from natural sources. The present study addresses the need for simple and user-friendly analytical methods for the fast and accurate quantification of heparin in complex matrices. Direct quantification of heparin in the low microgram per mL range was accomplished using a specific commercially available assay based on the fluorescent molecular probe Heparin Red, simply by mixing the heparin containing sample and a reagent solution in a 96-well microplate followed by fluorescence readout. A screening of typical impurities in raw heparin (selected other glycosaminoglycans, residual nucleic acids and proteins), related to the extraction from animal tissues, as well as of components of the urine matrix (inorganic salts, amino acids, trace proteins) revealed that these compounds even in large excess have no or very little effect on the accuracy of heparin determination. Heparin spike detection in urine, a biological multicomponent matrix, also showed good accuracy. We envision applications of this mix-and-read assay in the process and quality control in heparin manufacturing, but also in pharmacokinetic studies as a convenient tool for measuring of the urinary excretion of heparins.
Introduction
Heparins are widely used clinical anticoagulants [1, 2] , about one billion doses are produced each year. [3] Heparin is a polydisperse mixture of sulfated linear polysaccharides that consist of disaccharide repeating units (scheme 1, left) and have a high negative charge density of about -1.7 per monosaccharide. Unfractionated heparin (UFH, mean molecular weight between 13000 and 15000), is clinically applied since the 1930s. In recent decades, there has been a trend towards use of low molecular weight heparins (LMWH, mean molecular weight between 4000 and 7000). The latter are prepared from UFH by partial depolymerisation and display more favourable pharmacokinetics and lower side effects. In the following, the term "heparin" refers to unfractionated heparin.
Heparin is prepared by extraction from the tissues of slaughterhouse animals, mainly porcine intestine. The process involves protein hydrolysis at alkaline pH in the presence of proteases and enrichment of the heparin like GAGs by anion exchange resin. [4] The raw or crude heparin obtained at this stage is typically a mixture of many components -a rough estimate is 50% heparin and 50% other compounds [5] , mostly other glycosaminoglycans of lower sulfation degree (such as dermatan sulfate and chondroitin sulfate) but also residual biomaterials including proteins, peptides, nucleic acids, and lipids. Preparation of raw heparin is typically performed outside of GMP (Good Manufacturing Practices). There is a significant process-dependent variation in the composition of raw heparin. The crude material is then converted under GMP conditions to pharmaceutical grade heparin in a further multistep purification process, involving precipitation, ion exchange chromatography and chemical treatment. Monitoring the raw heparin preparation and purification process is challenging, and new, effective analytical methods for fast in-process quantification of heparin have the potential to improve production efficiency and reduce waste. [6] In 2008, the economically motivated adulteration of raw heparin with oversulfated chondroitin sulfate, a substance that mimics the anticoagulant activity of heparin but is much cheaper to produce, was associated with about 200 deaths and hundreds of adverse advents worldwide.
This "heparin crisis" has drawn renewed attention to the challenges that are associated with the characterization, quality control and standardisation of complex biological medicines from natural sources. [7] The tragic event resulted in the introduction of advanced analytical screening of pharmaceutical heparin, including NMR spectroscopy, capillary electrophoresis , and HPLC. To ensure continued safety of heparin, the US Food and drug administration (FDA) recommended continued development of additional methods for the quality control of heparin.
In clinical settings, heparin blood levels are monitored by the antithrombin-mediated effect on the clotting cascade or individual coagulation factors. These assays can, however, not be readily transferred to other complex matrices. Rather, heparin quantification in urine, for example, is achieved by challenging and time consuming protocols that either involve radiolabeling [8, 9] or require the isolation of heparin from urine and staining/colorimetric procedures, eventually including electrophoresis [10, 11] . Depending on the methodology, urinary recovery of heparin between 1% and 39 weight % of injected doses has been reported. In one study [10] , roughly one half of the excreted was characterized as unchanged heparin, and the other half as a partially desulfated metabolite with a charge density of about -1.5 per monosaccharide. There is a renewed recent interest in non-invasive (in particular oral) delivery options for heparin [12, 13] , and quantifying urinary excretion is part of the pharmacokinetic analysis. [14] Oral uptake of a 1000 U/kg body weight heparin dose resulted in urinary concentrations between 0,2 and 4 µg/mL. [14] There is a need for simple and user-friendly analytical methods for fast and accurate quantification of heparin in complex matrices. Such methods would be of great value for process control in crude heparin preparation and purification, assessing the comparibility of raw heparin batches in terms of heparin content, and for heparin quantification in complex biological matrices other than blood samples. A key requirement on such an assay is We describe here the application to heparin detection in various matrices of the fluorescent probe "Heparin Red", initially described as an experimental probe for heparin detection [16] and meanwhile developed further into commercially available assays. Heparin Red is a polyamine derivative of a red-emissive perylene diimide fluorophore (scheme 1, right). It forms a supramolecular complex with the target, with aggregation of the probe molecules at the heparin template and contact quenching of fluorescence (scheme 2). The strong binding of the polycationic probe to polyanionic heparin appears to be controlled by both electrostatic and aromatic pi-stacking interactions [17] . We have recently applied the commercial Heparin Red Kit, optimized for blood plasma matrix, to the direct quantification of heparins (including unfractionated heparin, low molecular weight heparin and non-anticoagulant heparins) and fucoidan (a polysulfated polysaccharide from brown algae) in human plasma. [18, 19] The Kit is of particulat value for non-anticoagulant heparins that can not be analyzed by standard coagulation assays and is emerging as a tool for pharmacokinetic analysis of this promising class of drug candidates. [20] While the Heparin Red Kit provides convincing results in the highly complex plasma matrix, it is prone to interference by nucleic acids (ususally not present in blood plamsa at signicant concentrations) and does not give satisfactory results for heparin detection in urine.
In this contribution, we describe for the first time the application of Heparin Red Ultra, a more recently released commercial assay, to heparin quantification in various matrices including urine. Heparin Red Ultra has a different reagent formulation and is provided as a ready-touse solution that simply needs to be mixed with the heparin containing sample. The study includes a systematic screening of the effect of individual components of raw heparin preparations and of the urine matrix on the accuracy of the assay. 
Materials and Methods

Instrumentation
Assays
Heparin Red® Ultra
For determination of heparin concentrations in aqueous or urine samples, the protocol of the provider for a 96-well microplate assay was followed. In brief, 5 µL of the heparin spiked sample was pipetted into a microplate well. Then, 180 µL of Heparin Red Ultra solution was added to the samples as simultaneously as possible. For samples numbers > 10, a 12-channel pipette was used for addititon of Heparin Red Ultra solution. The microplate was immediately introduced in the fluorescence reader and mixing was performed using the plate shaking function of the microplate reader (setting "high", 1 minute). Immediately after mixing, fluorescence was recorded within 1 minute. Detections in water and urine were performed as either duplicates or triplicates.
HemoCue® albumin 201 system
The Hemocue albumin 201 system is a portable, lab-accurate system for quantification of human serum albumin in urine. For determination of albumin concentrations in µg/mL, the protocol of the provider was followed.
Results and discussion
Detection of heparin in complex matrices
The Heparin Red Ultra assay was first applied to the detection of heparin at different concentrations in aqueous samples. Figure 1 shows the decrease of fluorescence signal with increasing heparin concentration. Response shows good linearity in the range 0-7 µg/mL. Analytical precision was determined for selected heparin concentrations, CVs relating to fluorescence internsity were 0.3% for c(heparin) = 0 µg/mL (n=8) and 2.9 % for c(heparin) = 4,38 µg/mL (n=8). At the latter concentration, an about 50% decrease of fluorescence intensity is observed. It should be noted at this point that, as described previously for the Heparin Red Kit [19] , the sensitivity of the assay is tunable by modification of the protocol. Increasing the sample volume from 5 µL (see "Materials and Methods", "Assays") to 10 µL enhances the sensitivity about twofold, i.e. only 0.4 µg/mL heparin trigger a 10% fluorescence reduction (data not shown). Also, the low molecular weight heparin enoxaparin is in 10 µL samples detected with good sensitivity (about 50% fluorescence reduction by 5 µg/mL, data not shown). The gain in sensitivity might, however, be at the cost of accuracy of the assay in the presence of potentially interfering compounds (figure 2).
To elicit the performance of the assay for heparin quantification in diverse matrices, we have repeated the assay at two heparin concentrations, 0 µg/mL (absence of heparin) and 4,38 µg/mL (about 50% reduction of fluorescence signal) in the presence of individual substances that are potential components of crude heparin preparations or of the urine matrix. These substances include inorganic salts, other glycosaminoglycans, proteins, amino acids and nucleic acids.
Results are shown in figure 2 . The control sample (leftmost in the diagram) refers to water and 4,38 µg/mL heparin in water, respectively. Fluorescence in the presence of most of the added substances at specified concentrations is within a narrow range, as indicated by the grey horizontal bars, of ± 2.6 % (heparin free samples) or ± 3.1 % (heparin spiked samples) from control, means no or very little interference. We conclude that the Heparin Red Ultra assay suppresses a wide variety of potential interferences in complex matrices.
In detail, the assay tolerates 150 mM NaCl, 75 mM KCl, and inorganic salts of di/trivalent ions (including Ca 2+ , Mg 2+ , sulfate and phosphate) in the 10-50 mg/mL range, nucleic acids (DNA, RNA) at 25-50 µg/mL, the glycosaminoglycans chondroitin sulfate an dermatan sulfate at 25 µg/mL, the amino acid glycine at 20 mM, immunoglubulin G (a major plasma protein, also present in urine in trace amounts) at 30 µg/mL, and a commercial protease preparation at 2 mg/mL (proteases are extensively used in the manufacture of crude heparin). Only human serum albumin (HSA), the most abundant plasma protein and potential trace protein in urine, strongly masks fluoresecence response to heparin in concentrations as low as 30 µg/mL. 
Detection of heparin in urine
Urine is a complex biological matrix. It is a multicomponent aqueous mixture of highly variable concentrations of inorganic salts, organic compounds and trace amounts of bioacromolecules including proteins and gylcosaminoglycans. figure 2 ). "Non-interfering level"
means that the fluorescence in the presence of these compounds is within ± 3.1 % of the control (compare figure 2 ). * Extrapolated from figure 2.
It is evident from table 1 that no or only little interference in the Heparin Red Ultra assay is expected from most of the listed urine components if present in their "normal" or reference range. A notable exception is, however, HSA which may significantly mask heparin response even at normal urinary levels (compare figure 3) .
In a preliminary evaluation, we have analysed two urine samples of healthy donors, either non-spiked or spiked with 4,38 µg/mL heparin ( figure 5 ). In one sample (urine 1), spike recovery was similar to that in water, while in the other sample (urine 2), fluorescence decrease was lower than expected and, consequently, spike recovery incomplete (figure 5).
We suspected that the masking effect of HSA was the origin of incomplete spike recovery.
This was confirmed by quantification of HSA in the urine samples, using an antibody-based turbidimetric detection method (Hemocue albumin 201 system). While in urine 1, HSA was not detectable (< 5 µg/mL, detection limit of the method), urine 2 displayed a HSA level of 5,5 µg/mL. The fluorescence response of the heparin-spiked urine 2 sample is in good agreement with that of an aqueous sample containing 5 µg/mL HSA (figure 3), supporting the idea that HSA partially masks the response of the assay in urine 2. 
Conclusion
This study addresses the need for simple and user-friendly analytical methods for the fast and accurate quantification of heparin in complex matrices. Commercially availbale Heparin
Red Ultra is a ready-to-use solution that is mixed with a small volume of heparin containing sample in a microplate well for one minute, followed by fluorescence readout. A screening of typical impurities related to industrial heparin extraction from animal tissues (selected glycosaminoglycans, residual nucleic acids and proteins) as well as of components of the urine matrix (inorganic salts, amino acids, trace proteins) revealed that these compounds even in large excess have no or very little effect on the accuracy of heparin determination.
Interference by human serum albumin appears to be related to extensive intramolecular disulfide bonding, a specific structural feature of this protein, and is readily overcome with a convenient sample pre-treatment protocol using the commercial disulfide cleaving agent tris(2-carboxyethyl)phosphine (TCEP). A preliminary evaluation of the fluorescence assay for heparin detection in urine, a complex multicomponent mixture, also revealed good accuracy. Heparin Red Ultra may facilitate process control of raw heparin preparation and purification in industrial manufacturing, support quality control of heparin batches, and allow convenient quantification of urinary excretion in pharmacokinetic studies.
